New members

New FACCNE member THERANOVIR: Transforming the Future of Cancer Treatment

Revolutionizing cancer treatment through groundbreaking Leptin/NRP-1/OBR-targeted immunotherapies, led by its First-in-Class antibody, NOV2.

FACCNE is proud to welcome THERANOVIR as a new member of our community!

THERANOVIR is leveraging the complex Leptin/NRP-1/OBR signaling platform to develop next-generation immunotherapeutics addressing major global health challenges, including cancer, obesity, and viral infections.

At the forefront of THERANOVIR’s pipeline is NOV2, a First-in-Class monoclonal antibody that stands out for its unique mechanism of action. Unlike conventional therapies, NOV2 can penetrate the nucleus of tumor cells without conjugation, inducing DNA damage, telomere shortening, and stimulating a robust anti-tumor immune response.

NOV2 holds promise for patients with both solid and liquid tumors expressing the Leptin/NRP-1/OBR complex. Its versatility allows for effective combination with radiotherapy, chemotherapy, or immunotherapy, or as a carrier for radiopharmaceuticals or chemotherapy agents.

Through this innovative approach, THERANOVIR is redefining immunotherapy and opening new horizons in precision cancer treatment.

For more information: https://www.theranovir.com/